Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclocreatine SCHEMBL7935371 | 0.73 | CYP2D6 (0.39) | ALDH1A1POLB | |
| Cyclocreatine SCHEMBL450343 | 0.73 | CYP2D6 (0.39) | ALDH1A1POLB | |
| SCHEMBL856041 | 0.72 | — | — | |
| Cyclocreatine SCHEMBL11796002 | 0.72 | CYP2D6 (0.38) | ALDH1A1POLB | |
| SCHEMBL14537232 | 0.72 | BDKRB2 (0.33) | — | |
| SCHEMBL19719147 | 0.72 | — | — | |
| SCHEMBL9889349 | 0.71 | — | — | |
| SCHEMBL13248108 | 0.71 | — | — | |
| SCHEMBL938191 | 0.71 | KMT2A (0.39) | ALDH1A1POLB | |
| Bromide SCHEMBL31141398 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240180912-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | INSPIRNA, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| US-20230285338-A9 | METHODS FOR TREATING MICROGLIAL DYSFUNCTION | WASHINGTON UNIVERSITY | 2023-09-14 | — | — | US | disclosed |
| US-20230285338-A9 | METHODS FOR TREATING MICROGLIAL DYSFUNCTION | WASHINGTON UNIVERSITY | 2023-09-14 | — | — | US | disclosed |
| WO-2023004308-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | INSPIRNA, INC. (US) | 2023-01-26 | — | — | WO | disclosed |
| EP-3950673-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | Inspirna, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3950673-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | Inspirna, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| US-20210393563-A1 | METHODS FOR TREATING MICROGLIAL DYSFUNCTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-12-23 | — | — | US | disclosed |
| EP-3137447-B1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | RGENIX INC (US) | 2021-06-30 | — | — | EP | disclosed |
| EP-3137447-B1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | RGENIX INC (US) | 2021-06-30 | — | — | EP | disclosed |
| US-10717704-B2 | Inhibitors of creatine transport and uses thereof | RGENIX, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-20080119450-A1 | Use of creatine or creatine analogs for the treatment of diseases of the nervous system | AVICENA GROUP, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20070253944-A1 | Use of creatine or creatine compounds for skin preservation | AVICENA GROUP, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070253944-A1 | Use of creatine or creatine compounds for skin preservation | AVICENA GROUP, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-7285573-B2 | Use of creatine or creatine analogs for the treatment of diseases of the nervous system | AVICENA GROUP, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| US-7285573-B2 | Use of creatine or creatine analogs for the treatment of diseases of the nervous system | AVICENA GROUP, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| US-7186754-B2 | Use of creatine or creatine compounds for skin preservation | AVICENA GROUP, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186754-B2 | Use of creatine or creatine compounds for skin preservation | AVICENA GROUP, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-6706764-B2 | TREATMENT OF DIABETIC AND TOXIC NEUROPATHIES, PERIPHERAL NERVOUS SYSTEM DISEASES, ALZHEIMER DISEASE, PARKINSON'S DISEASE, STROKE, HUNTINGTON'S DISEASE, AMYOTROPIC LATERAL SCLEROSIS | AVICENA GROUP, INC. | 2004-03-16 | — | — | US | disclosed |
| US-6706764-B2 | TREATMENT OF DIABETIC AND TOXIC NEUROPATHIES, PERIPHERAL NERVOUS SYSTEM DISEASES, ALZHEIMER DISEASE, PARKINSON'S DISEASE, STROKE, HUNTINGTON'S DISEASE, AMYOTROPIC LATERAL SCLEROSIS | AVICENA GROUP, INC. | 2004-03-16 | — | — | US | disclosed |
| WO-1996016629-A2 | PHOSPHINIC CREATINE COMPOUNDS HAVING ANTIVIRAL ACTIVITY | AMIRA INC (US) | 1996-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240180912-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | KRAS, FOLR2, SLC19A1 | ALDH1A1 1159/4885POLB 262/4885 |
| US-10717704-B2 | Inhibitors of creatine transport and uses thereof | CKMT1A; CKMT1B, SLC25A1, SLC2A1 | ALDH1A1 2023/4885POLB 1948/4885 |
| US-20070253944-A1 | Use of creatine or creatine compounds for skin preservation | PC, CKMT1A; CKMT1B, CHEK1 | ALDH1A1 2904/4885POLB 352/4885 |
| US-20210393563-A1 | METHODS FOR TREATING MICROGLIAL DYSFUNCTION | CHRNB2, PSEN2, CX3CR1 | ALDH1A1 2323/4885POLB 3048/4885 |
| US-20230285338-A9 | METHODS FOR TREATING MICROGLIAL DYSFUNCTION | CX3CR1, CD68, FYN | ALDH1A1 3841/4885POLB 3178/4885 |
| US-20080119450-A1 | Use of creatine or creatine analogs for the treatment of diseases of the nervous system | CKMT1A; CKMT1B, PC, PCK2 | ALDH1A1 4225/4885POLB 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.